Skip to main content
NAII
NASDAQ Life Sciences

Secures $31M High-Interest Debt, Plans HQ Sale Amid Deepening Losses

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$2.59
Mkt Cap
$15.998M
52W Low
$2.33
52W High
$4.96
Market data snapshot near publication time

summarizeSummary

Natural Alternatives International Inc. secured a new $31.0 million high-interest credit facility and plans to sell its corporate headquarters to address liquidity needs and ongoing financial losses, including prior debt covenant violations.


check_boxKey Events

  • New $31.0 Million High-Interest Credit Facility

    The company entered into a new Loan and Security Agreement with Legacy Corporate Lending, LLC, including an $11.0 million term loan and a $20.0 million working capital line of credit. The term loan carries an initial interest rate of 14.0% (then SOFR + 5.0%), and the line of credit is at SOFR + 4.5%, significantly higher than previous rates, indicating financial distress.

  • Plans to Sell Corporate Headquarters

    Management has determined to sell the corporate headquarters building to gain enhanced financial flexibility and additional liquidity, citing recent operating challenges and the need to redeploy capital for new initiatives and working capital.

  • Deteriorating Financial Performance

    For the quarter ended March 31, 2026, net loss increased by 97% to $(4.31) million, and cash used in operating activities for the nine-month period was $(7.85) million, a significant deterioration from the prior year's cash generation.

  • Prior Debt Covenant Violations

    The company was not in compliance with the maximum net loss and fixed charge coverage ratio covenants of its previous Wells Fargo credit agreement, which the new financing facility addresses.


auto_awesomeAnalysis

Natural Alternatives International Inc. has secured a new $31.0 million credit facility with Legacy Corporate Lending, LLC, comprising an $11.0 million term loan and a $20.0 million working capital line of credit. This refinancing replaces their previous Wells Fargo debt, which the company was not in compliance with due to covenant violations (maximum net loss and fixed charge coverage ratio). The new financing comes at a significantly higher cost, with the term loan initially bearing 14.0% interest (then SOFR + 5.0%) and the line of credit at SOFR + 4.5%, compared to the prior SOFR + 1.8% and SOFR + 3.25% rates, respectively. This substantial increase in borrowing cost, coupled with the company's decision to sell its corporate headquarters for enhanced financial flexibility and liquidity, highlights severe financial challenges. The company reported a 97% increase in net loss for the quarter to $(4.31) million and a significant cash burn of $(7.85) million from operations for the nine-month period, further underscoring its urgent need for capital.

At the time of this filing, NAII was trading at $2.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16M. The 52-week trading range was $2.33 to $4.96. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed NAII - Latest Insights

NAII
May 19, 2026, 6:03 AM EDT
Filing Type: 10-Q
Importance Score:
9
NAII
May 01, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
NAII
Mar 20, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
NAII
Feb 13, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
9